Tinengotinib (TT-00420), a Novel Spectrum-Selective Small-Molecule Kinase Inhibitor, Is Highly Active Against Triple-Negative Breast Cancer

Triple-negative breast cancer (TNBC) is a highly heterogeneous cancer lacking actionable targets. Using a phenotypic screen of TNBC cells, we discovered a novel multiple kinase inhibitor tinengotinib (TT-00420) that strongly inhibited Aurora A/B, FGFR1/2/3, VEGFRs, JAK1/2, and CSF1R in biochemical a...

Descripción completa

Detalles Bibliográficos
Autores principales: Peng, Peng, Qiang, Xiaoyan, Li, Guoyu, Li, Lin, Ni, Shumao, Yu, Qi, Sourd, Laura, Marangoni, Elisabetta, Hu, Chao, Wang, Dong, Wu, Di, Wu, Frank
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2023
Materias:
Small Molecule Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9890131/
https://www.ncbi.nlm.nih.gov/pubmed/36223547
http://dx.doi.org/10.1158/1535-7163.MCT-22-0012

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9890131/
https://www.ncbi.nlm.nih.gov/pubmed/36223547
http://dx.doi.org/10.1158/1535-7163.MCT-22-0012

Ejemplares similares